Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL495695 | 1.00 | SLC18A3 (0.75) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL495697 | 1.00 | SLC18A3 (0.75) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL4573453 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL2173028 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL2175594 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL30098419 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Methylene Chloride SCHEMBL28313080 | 0.92 | SLC18A3 (0.64) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28296851 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28298515 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28298504 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035580-A | Novel piperazinyl sulfonamides and their use as neuroprotective and/or neurorestorative agents | 基因密码公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119606059-A | Preparation method of filter element material for enhancing tobacco smoke adsorption | 奥伯风环境科技(南京)有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| EP-2970119-B1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | claimed |
| US-11052082-B2 | Combination of opioids and anticancer drugs for cancer treatment | UNIVERSITÄT ULM (DE) | 2021-07-06 | — | — | US | claimed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | claimed |
| CN-1859914-A | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | claimed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | claimed |
| CN-1646499-A | Fused pyridazine derivative compounds and drugs containing these compounds as active ingredients | ONO PHARMACEUTICAL CO (JP) | 2005-07-27 | — | — | CN | claimed |
| US-5545647-A | PHOSPHODIESTERASE INHIBITORS; ANTIASTHMATICS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-08-13 | — | — | US | claimed |
| EP-0671389-A1 | 3-Phenylpyrrolidine derivatives | Mitsubishi Chemical Corporation (JP) | 1995-09-13 | — | — | EP | claimed |
| EP-0431856-B1 | Heterocyclic compounds | ZENECA LTD (GB) | 1995-07-12 | — | — | EP | claimed |
| EP-0309913-B1 | Fungicidal N-substituted 3-aryl-pyrrolidine derivatives | BASF AG (DE) | 1994-06-15 | — | — | EP | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| EP-0309913-A2 | Fungicidal N-substituted 3-aryl-pyrrolidine derivatives | BASF Aktiengesellschaft (DE) | 1989-04-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | SLC18A3 3832/4885SIGMAR1 2649/4885HTR3A 1178/4885 |
| US-11052082-B2 | Combination of opioids and anticancer drugs for cancer treatment | OPRM1, OPRL1, OPRK1 | SLC18A3 382/4885SIGMAR1 7/4885HTR3A 72/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | SLC18A3 477/4885SIGMAR1 1483/4885HTR3A 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.